Prot #VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/M

Project: Research project

Project Details

Effective start/end date6/5/186/5/21


  • Greenphire, Inc. (Prot #VX17-445-102 // Prot #VX17-445-102)
  • Vertex Pharmaceuticals Incorporated (Prot #VX17-445-102 // Prot #VX17-445-102)